Trust Signals
Key Takeaways
- The half life of liraglutide is 13 hours after subcutaneous injection, established in the FDA prescribing information from pharmacokinetic studies across the LEAD trial program.
- Peak plasma concentration (Tmax) occurs 8 to 12 hours post-injection, meaning the drug is still rising for nearly half a day after you inject it.
- Steady state is achieved after approximately 3 to 4 days of daily dosing, not immediately, which is why dose-titration periods should not be shortened.
- Liraglutide's 13-hour half life is produced by a single structural modification: a C16 fatty acid chain that drives reversible albumin binding, shielding it from DPP-4 enzyme degradation.
- Semaglutide's half life is roughly 165 to 184 hours (about 7 days), approximately 13 times longer than liraglutide, which explains the entire weekly versus daily dosing difference.
What Is the Half Life of Liraglutide? (Direct Answer)
The half life of liraglutide is approximately 13 hours after subcutaneous injection. This figure, from the FDA prescribing information for Victoza and Saxenda, supports once-daily dosing. Five half-lives, approximately 65 hours or just under 3 days, are required for the drug to fall below 3 percent of peak levels.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is the half life of liraglutide? (Direct answer)
- Why does liraglutide last 13 hours? The structural chemistry
- Full pharmacokinetic timeline: absorption to elimination
- Evidence ledger: what the data actually support
- How long does liraglutide stay in your system?
- Steady state: when does liraglutide fully kick in?
- What most pages get wrong about liraglutide half life
- Missed dose math: what actually happens to blood levels
- Honest head-to-head: liraglutide vs. semaglutide pharmacokinetics
- Does renal or hepatic impairment change the timeline?
- Operational guide: reading a COA and dosing table
- FAQ
- Sources
Why Does Liraglutide Last 13 Hours? The Structural Chemistry
Native GLP-1 has a plasma half life of 1 to 2 minutes. The enzyme dipeptidyl peptidase-4 (DPP-4) cleaves the His-Ala bond at positions 1 to 2, inactivating it almost immediately. Neutral endopeptidase contributes additional degradation. The result: native GLP-1 is clinically useless as a drug because it cannot survive long enough to act.
Liraglutide extends survival through one primary structural change. A C16 fatty acid (palmitic acid) is attached via a gamma-glutamate spacer to lysine at position 26 of the GLP-1 backbone. This fatty acid chain binds reversibly to albumin in plasma. Albumin binding does two things simultaneously:
- It sterically blocks DPP-4 from accessing the cleavage site, reducing enzymatic degradation dramatically.
- It increases the apparent molecular weight of the complex above the renal filtration threshold, slowing renal clearance.
The result is a half life extension from minutes to 13 hours. Importantly, the albumin binding is reversible and in equilibrium, so free liraglutide is continuously available to activate GLP-1 receptors while the bound fraction acts as a circulating reservoir. This is also why liraglutide bioavailability after subcutaneous injection is approximately 55 percent rather than 100 percent: a portion is degraded locally and in transit before reaching systemic circulation.
Full Pharmacokinetic Timeline: Absorption to Elimination
| Timepoint | What Happens | Key Number |
|---|---|---|
| 0 hours (injection) | Subcutaneous depot forms; slow absorption begins | Bioavailability ~55% |
| 8 to 12 hours | Peak plasma concentration (Tmax) reached | Tmax 8 to 12 h (prescribing information) |
| 13 hours post-peak | Concentration falls to 50% of Cmax | t1/2 = 13 h |
| 3 to 4 days (daily dosing) | Steady-state concentration achieved | ~4 to 5 half-lives to accumulate |
| 65 hours post-last dose | Drug below 3% of Cmax (5 half-lives) | ~2.7 days washout |
Volume of distribution is approximately 11 to 17 liters after subcutaneous dosing, indicating limited distribution beyond the vascular and interstitial space, consistent with the large albumin-bound complex. Liraglutide is not a CYP450 substrate, so it does not produce classic hepatic drug-drug interactions.
Evidence Ledger: What the Data Actually Support
| Claim | Best Evidence Type | Source / Trial | Direction | Confidence |
|---|---|---|---|---|
| Half life = 13 hours | Human PK studies, multiple doses | FDA Victoza/Saxenda prescribing information; LEAD PK analyses | Confirmed | High |
| Tmax = 8 to 12 hours | Human PK studies | FDA prescribing information | Confirmed | High |
| Bioavailability ~55% | Human radiolabeled study | FDA prescribing information | Confirmed | High |
| Steady state in 3 to 4 days | Human PK modeling | Prescribing information; consistent with half life math | Confirmed | High |
| Albumin binding prolongs half life | Mechanism / structural chemistry | Drucker et al., published pharmacology reviews | Established mechanism | High (mechanistic) |
| Mild renal impairment has minimal PK impact | Human PK sub-study | FDA prescribing information renal section | Minimal effect confirmed | Moderate |
| Severe renal impairment safety | Limited human data | Prescribing information caution language | Uncertain | Low |
| No CYP450-based drug interactions | In vitro and human PK | Prescribing information drug interaction section | Confirmed for major CYPs | High |
How Long Does Liraglutide Stay in Your System?
Using the standard 5 half-lives rule, liraglutide falls below clinically meaningful concentrations approximately 65 hours after the last dose. That is about 2.7 days. In practical terms:
- 24 hours after last dose: roughly 15 to 20 percent of steady-state trough remains (two half-lives from the trough point).
- 48 hours after last dose: the drug is largely but not fully cleared.
- 72 hours (3 days): effectively cleared for most clinical purposes.
Note that GLP-1 receptor effects (appetite suppression, gastric emptying delay) may partially persist beyond measurable plasma levels due to receptor desensitization kinetics, though this is less pronounced with liraglutide than with longer-acting agents.
Steady State: When Does Liraglutide Fully Kick In?
Steady state is reached when the rate of drug input equals the rate of elimination, which mathematically occurs after 4 to 5 half-lives of consecutive dosing. At a 13-hour half life with once-daily dosing (24-hour interval), this means 3 to 4 days of daily injections produces stable trough and peak concentrations.
This is clinically important for titration. Liraglutide is typically started at 0.6 mg daily for one week before advancing to 1.2 mg (for type 2 diabetes) or continuing a weekly titration schedule up to 3.0 mg (for weight management). The one-week step intervals give the drug more than enough time to reach steady state at each dose before assessment, but the rationale for weekly intervals is primarily GI tolerability, not PK lag.
What Most Pages Get Wrong About Liraglutide Half Life
First, liraglutide peaks at 8 to 12 hours and then declines. The drug is active and rising during the first 8 to 12 hours, not declining. Second, at steady state (after 3 to 4 days of daily dosing), the trough concentration before the next daily injection is still pharmacologically active. The peak-to-trough ratio at steady state is approximately 2-fold per prescribing information, meaning even the lowest daily blood level is not zero or sub-therapeutic.
A second common error: conflating liraglutide's PK with exenatide (Byetta), an older GLP-1 agonist with a much shorter half life of roughly 2.4 hours that requires twice-daily dosing. Liraglutide and exenatide are different molecules with profoundly different pharmacokinetics.
A third omission: most pages do not mention that liraglutide's ~55 percent subcutaneous bioavailability means the delivered systemic dose is meaningfully less than the injected dose. A 1.8 mg injection delivers roughly 1.0 mg of systemic exposure in bioavailability terms.
Missed Dose Math: What Actually Happens to Blood Levels
At steady state, skipping a single daily dose creates a predictable concentration drop. Starting from the typical trough (lowest point before the next injection):
| Hours After Missed Dose Time | Approximate Remaining Drug Level (vs. Trough) |
|---|---|
| 0 hours (missed) | 100% of trough (no new drug added) |
| 13 hours | ~50% of trough |
| 24 hours | ~25% of trough (roughly 2 half-lives from trough) |
| 36 hours | ~12% of trough |
The prescribing information guidance: if a dose is missed and fewer than 12 hours remain until the usual injection time, skip it. If more than 12 hours remain, take it when remembered. Never double-dose. Resuming the next day restores steady state within 1 to 2 days.
Honest Head-to-Head: Liraglutide vs. Semaglutide Pharmacokinetics
| Parameter | Liraglutide | Semaglutide (SC) | Winner |
|---|---|---|---|
| Half life | 13 hours | 165 to 184 hours (~7 days) | Semaglutide (convenience) |
| Dosing frequency | Once daily | Once weekly | Semaglutide (adherence) |
| Time to peak (Tmax) | 8 to 12 hours | 24 to 72 hours | Liraglutide (faster peak) |
| Washout time (5 half-lives) | ~65 hours (~3 days) | ~5 to 6 weeks | Liraglutide (faster clearance when needed) |
| Bioavailability (SC) | ~55% | ~89% | Semaglutide |
| CYP450 interactions | None significant | None significant | Tie |
| Titration complexity | Weekly dose steps over 4 to 5 weeks | Monthly dose steps | Semaglutide (simpler schedule) |
| If side effects occur: reversal speed | Resolved in ~3 days | May take weeks | Liraglutide (faster offset) |
Liraglutide wins precisely one category that matters clinically: faster offset. If a patient develops pancreatitis, severe GI intolerance, or needs emergency surgery, liraglutide clears in 3 days versus semaglutide's weeks-long tail. That shorter half life is a genuine advantage in those scenarios, not merely a dosing inconvenience.
Does Renal or Hepatic Impairment Change the Timeline?
Liraglutide is not renally eliminated as intact drug, and it is not a CYP450 substrate, so the classic hepatic and renal clearance pathways are largely irrelevant. However:
- Renal impairment: The prescribing information reports no clinically meaningful difference in liraglutide exposure across mild, moderate, or severe renal impairment groups in dedicated PK sub-studies, though severe impairment data are limited. The FDA labeling notes that use in end-stage renal disease is not recommended due to limited experience, not due to known PK changes.
- Hepatic impairment: Mild and moderate hepatic impairment produced modest reductions in liraglutide exposure in sub-studies, not increases. This is thought to relate to altered albumin synthesis (reducing the albumin reservoir). Severe hepatic impairment is not recommended.
- Body weight: Higher body weight is associated with modestly higher apparent volume of distribution, but population PK analyses incorporated in the SCALE trial reports show this does not meaningfully alter the 13-hour half life estimate across the studied weight range.
Operational Guide: Reading a COA and Dosing Reference
For compounded liraglutide (available through 503B outsourcing facilities in the United States), a certificate of analysis (COA) should include:
| COA Field | What to Look For | Red Flag |
|---|---|---|
| Identity | HPLC or mass spectrometry confirmation of liraglutide | Identity listed as "GLP-1 analog" without specific confirmation |
| Purity | Greater than 98% by HPLC is standard for peptide injectables | Purity below 95% or not stated |
| Endotoxin | Below USP limits for injectable preparations (typically less than 5 EU/mL) | No endotoxin test listed |
| pH | 7.0 to 7.8 for injectable solution (consistent with Victoza formulation) | pH outside physiologic range |
| Sterility | USP sterility testing passed | Visual inspection only noted |
| Lot and expiry | Specific lot number and beyond-use date | No expiry date |
Storage reality: Liraglutide in solution is stable at 2 to 8 degrees Celsius (refrigerated) until the expiry date. After first use of the branded pen, Victoza prescribing information states it may be stored at room temperature (below 30 degrees Celsius) or refrigerated for up to 30 days. The mechanism of degradation at higher temperatures is peptide bond hydrolysis and aggregation, accelerated by heat and light exposure. A degraded solution may appear cloudy or contain particulates; do not use if this occurs. Freezing denatures the protein structure and is explicitly contraindicated.
Dosing reference table (Saxenda titration, weight management indication):
| Week | Dose | Rationale |
|---|---|---|
| 1 | 0.6 mg daily | GI tolerance, not therapeutic target |
| 2 | 1.2 mg daily | Approaching therapeutic range |
| 3 | 1.8 mg daily | Mid-therapeutic |
| 4 | 2.4 mg daily | Near target |
| 5 onward | 3.0 mg daily | Full approved weight management dose |
Each dose step is held for one week. Given the 3 to 4 day steady-state window, the weekly interval captures at least 2 to 3 days of true steady state before evaluation, which is appropriate.
FAQ
What is the half life of liraglutide?
The half life of liraglutide is approximately 13 hours after subcutaneous injection, as established in the FDA-approved prescribing information for Victoza and Saxenda. This enables once-daily dosing with reasonable trough coverage.
How long does liraglutide stay in your system?
After 5 half-lives (roughly 65 hours, or about 2.7 days), liraglutide falls below 3 percent of its peak concentration. Clinically meaningful drug levels are essentially gone within 3 days of the last dose for most individuals.
How long does it take liraglutide to reach steady state?
Steady state is reached after approximately 3 to 4 days of once-daily dosing, consistent with the 13-hour half life requiring roughly 4 to 5 half-lives to accumulate. Peak-to-trough fluctuation at steady state is about 2-fold based on prescribing information pharmacokinetic data.
When does liraglutide peak after injection?
Liraglutide reaches its peak plasma concentration (Tmax) at 8 to 12 hours after a subcutaneous dose, regardless of injection site (abdomen, thigh, or upper arm). The Tmax is largely independent of dose within the therapeutic range.
What happens if I miss a dose of liraglutide?
If fewer than 12 hours have passed since the missed dose time, take it as soon as remembered. If more than 12 hours have passed, skip it and resume the next scheduled dose. Do not double dose. Because the half life is 13 hours, a single missed day means levels drop to roughly 50 percent of steady-state trough by 13 hours and to about 25 percent by 26 hours.
How does liraglutide half life compare to semaglutide?
Semaglutide has a half life of approximately 165 to 184 hours (about 7 days), which is roughly 13 times longer than liraglutide's 13 hours. This is why semaglutide is dosed once weekly while liraglutide requires daily injections.
Does obesity or body weight affect liraglutide half life?
The prescribing information notes modest pharmacokinetic variation by body weight, but the 13-hour half life figure is derived from the obese population studied in the SCALE and LEAD trials. Body weight does affect apparent volume of distribution more than elimination half life itself.
Does kidney or liver disease change how long liraglutide lasts?
Mild to moderate renal impairment has minimal clinically meaningful impact on liraglutide exposure per prescribing information studies. Mild to moderate hepatic impairment shows modestly reduced exposure. Severe renal or hepatic impairment data are limited, and use in these populations warrants caution.
Why does liraglutide last 13 hours when native GLP-1 lasts only minutes?
Native GLP-1 is degraded within 1 to 2 minutes by the enzyme DPP-4 and neutral endopeptidase. Liraglutide is structurally modified: a C16 fatty acid chain is attached via a glutamate-linker at position 26, enabling albumin binding. Albumin binding shields liraglutide from DPP-4 cleavage and slows renal filtration, extending the half life to 13 hours.
What is the washout period for liraglutide before switching drugs?
Using the 5 half-lives rule, liraglutide is pharmacokinetically cleared in approximately 65 hours (under 3 days). However, clinical guidelines and prescribing information for transitioning to other GLP-1 agents or managing adverse effects typically use a 3-day practical washout as a conservative minimum.
How is liraglutide metabolized and eliminated?
Liraglutide is metabolized endogenously in a manner similar to large proteins, through peptide bond cleavage rather than hepatic CYP450 pathways. Intact drug is not excreted in urine or bile. Radiolabeled studies show metabolites appear in urine and feces, but no single organ is the primary elimination site.
Does injection site affect liraglutide absorption or half life?
Pharmacokinetic studies show that absorption rate and Tmax are comparable across approved injection sites (abdomen, thigh, upper arm). The half life is not meaningfully altered by injection site. Bioavailability is approximately 55 percent regardless of site.
Sources
- U.S. Food and Drug Administration. Victoza (liraglutide) Prescribing Information. Novo Nordisk. Revised 2017. Available at: FDA.gov.
- U.S. Food and Drug Administration. Saxenda (liraglutide 3 mg) Prescribing Information. Novo Nordisk. Revised 2021. Available at: FDA.gov.
- Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705.
- Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in type 2 diabetic patients with and without a prior history of cardiovascular disease: no difference in cardiovascular risk profile. Clin Pharmacol Drug Dev. 2016;5(2):136-143. (Population PK analysis referencing prescribing information parameters.)
- European Medicines Agency. Victoza Assessment Report. EMA/CHMP. 2009. Available at: EMA.europa.eu.
- Nauck MA et al. (LEAD program publications). Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes. Diabetes Care. 2009;32(7):1207-1214.
- Davies MJ, et al. (SCALE Obesity and Prediabetes, principal investigators). Efficacy of liraglutide for weight loss among patients with type 2 diabetes. JAMA. 2015;314(7):687-699.
- Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155.